1. Home
  2. PCB vs OCGN Comparison

PCB vs OCGN Comparison

Compare PCB & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PCB Bancorp

PCB

PCB Bancorp

N/A

Current Price

$21.62

Market Cap

325.6M

Sector

Finance

ML Signal

N/A

Logo Ocugen Inc.

OCGN

Ocugen Inc.

HOLD

Current Price

$1.35

Market Cap

387.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCB
OCGN
Founded
2003
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
325.6M
387.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PCB
OCGN
Price
$21.62
$1.35
Analyst Decision
Hold
Strong Buy
Analyst Count
2
2
Target Price
$24.50
$7.00
AVG Volume (30 Days)
27.4K
3.9M
Earning Date
01-29-2026
11-05-2025
Dividend Yield
3.71%
N/A
EPS Growth
43.50
N/A
EPS
2.41
N/A
Revenue
$107,743,000.00
$5,370,000.00
Revenue This Year
$21.55
$35.93
Revenue Next Year
$8.65
N/A
P/E Ratio
$8.95
N/A
Revenue Growth
13.61
14.26
52 Week Low
$16.00
$0.52
52 Week High
$24.04
$1.90

Technical Indicators

Market Signals
Indicator
PCB
OCGN
Relative Strength Index (RSI) 40.31 48.84
Support Level $23.03 $1.34
Resistance Level $24.04 $1.53
Average True Range (ATR) 0.59 0.11
MACD -0.23 0.00
Stochastic Oscillator 2.76 36.49

Price Performance

Historical Comparison
PCB
OCGN

About PCB PCB Bancorp

PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.

About OCGN Ocugen Inc.

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Share on Social Networks: